<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03820466</url>
  </required_header>
  <id_info>
    <org_study_id>GRAY-ZONE</org_study_id>
    <nct_id>NCT03820466</nct_id>
  </id_info>
  <brief_title>Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin</brief_title>
  <acronym>GRAY-ZONE</acronym>
  <official_title>Investigator-initiated, Placebo-controlled, Randomized Trial to Assess the Efficacy and Safety of Platelet Inhibition and/ or Lipid Lowering in Non-ACS-patients With Elevated High-sensitivity Troponin Values</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. med. Mahir Karakas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the effect of platelet inhibition and / or lipid lowering in&#xD;
      non-ACS-patients with symptoms suggestive for ACS, and elevated high-sensitivity troponin&#xD;
      values&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current databases show, that high-/ ultra sensitive (hs)/ (us) troponin levels above the 99th&#xD;
      percentile in patients presenting with chest pain are indicative for future cardiovascular&#xD;
      events, even when acute coronary syndrome (ACS) was ruled out. Most of these non-ACS-patients&#xD;
      are discharged without specific/ preventive therapy (anti-platelet or anti-lipid), although&#xD;
      &quot;positive&quot; troponin values (any value at any time during hospitalisation above the 99th&#xD;
      percentile) seem to clearly indicate underlying myocardial ischemia. In summary, there is an&#xD;
      unmet need and huge potential to reduce mortality and morbidity in Chest Pain Unit patients&#xD;
      by specific therapy. The investigators propose that platelet inhibition by Aspirin or lipid&#xD;
      lowering by Atorvastatin will prevent plaque rupture and superimposition of thrombosis to&#xD;
      coronary atherosclerosis in this population. It is planned to conduct a controlled clinical&#xD;
      trial: 3,000 troponin positive patients presenting at emergency room (ER)/ CPU with symptoms&#xD;
      suggestive for ACS, but an ACS was ruled out, will be assigned randomly to Aspirin 100 mg&#xD;
      and/ or Atorvastatin 20 mg versus placebo (2x2 factorial design).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial infarction and/ or cardiovascular death and/ or revascularization</measure>
    <time_frame>Until last patient has completed 12 months of follow-up</time_frame>
    <description>Time to myocardial infarction, coronary revascularization, or death, whatever comes first</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Acute Chest Syndrome</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin 100 mg once daily and Placebo Atorvastatin once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin 20 mg once daily and Placebo Aspirin once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin-Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin 100 mg once daily and Atorvastatin 20 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Aspirin once daily and Placebo Atorvastatin once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Once daily application of platelet inhibiting medication</description>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_label>Aspirin-Atorvastatin</arm_group_label>
    <other_name>Acetyl Salicyl Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Once daily application of lipid lowering medication</description>
    <arm_group_label>Aspirin-Atorvastatin</arm_group_label>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>Statin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Aspirin</intervention_name>
    <description>Once daily application of placebo</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo Oral Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Atorvastatin</intervention_name>
    <description>Once daily application of placebo</description>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo Oral Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with symptoms suggestive for ACS presenting within 48 hours after onset in the&#xD;
             ER/ Chest Pain Unit (CPU)&#xD;
&#xD;
          -  Patient has at least one elevated high-sensitivity troponin I or T value&#xD;
&#xD;
          -  Chest pain is classified as non-ACS, despite elevated hsTn (e.g. because of missing&#xD;
             troponin dynamics)&#xD;
&#xD;
          -  At least 50 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Indication for antiplatelet therapy (e.g transient ischemic attack, or stable coronary&#xD;
             artery diseases -CAD) or anticoagulation therapy (such as atrial fibrillation)&#xD;
&#xD;
          -  Indication for anti-lipid therapy&#xD;
&#xD;
          -  Any evidence of an acute myocardial necrosis (e.g imaging evidence of new regional&#xD;
             wall motion abnormality, or significant ST-segment-T wave (ST-T) changes in ECG)&#xD;
&#xD;
          -  Untreated clinically significant CAD requiring revascularization&#xD;
&#xD;
          -  Hemoglobin value below 8 mg/d, and/or creatinine kinase ≥3 times ULN, and/or AST or&#xD;
             ALT ≥3 times ULN&#xD;
&#xD;
          -  Active malignancy of any organ system, treated or untreated. Subjects have to be in&#xD;
             remission for at least 36 months to be eligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahir Karakas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Heart Center Hamburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahir Karakas, MD</last_name>
    <phone>+4915222817493</phone>
    <email>m.karakas@uke.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Berlin, Campus Benjamin-Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulf Landmesser, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asklepios Harz-Hospital Goslar</name>
      <address>
        <city>Goslar</city>
        <zip>38642</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Wittlinger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Heart Center Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahir Karakas, MD, MBA</last_name>
      <phone>+4915222817493</phone>
      <email>m.karakas@uke.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moritz Biener, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rolf Wachter, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Hospital Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Storm, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mirjam Kessler, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 2, 2017</study_first_submitted>
  <study_first_submitted_qc>January 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2019</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsklinikum Hamburg-Eppendorf</investigator_affiliation>
    <investigator_full_name>Dr. med. Mahir Karakas</investigator_full_name>
    <investigator_title>Coordinating Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Aspirin</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>Troponin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Chest Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

